Adcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.
Tag Archive for: Andtibody-drug conjugates
Yumab GmbHAntibody-drug conjugates (ADCs) hinge on the antibody, not merely the payload or linker. Antibody precision defines efficacy, safety and therapeutic window. Emerging antibody formats – bispecifics, conditional designs and TCR-mimics – expand target space, demanding rigorous engineering to realise next-generation ADC potential.